Obsidian Therapeutics (OBX) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $741.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OBX | SNDX |
|---|---|---|
| Share price | $12.00 | $8.72 |
| Market cap | $741.29M | $785.05M |
| 1-day change | -1.23% | -4.49% |
| YTD return | — | -58.50% |
| 1-year return | — | -50.00% |
| 5-year return | — | -47.09% |
| EPS (TTM) | $-6.52 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $172.35M |
| Revenue growth (YoY) | — | +627.84% |
| Net income (latest FY) | — | $-285.42M |
| Operating margin | — | -158.45% |
| Net margin | — | -165.60% |
| 52-week high | $49.97 | $25.59 |
| 52-week low | $9.60 | $8.41 |
| Distance from 52-week high | -75.99% | -65.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +222.25% | +306.54% |
| Average volume | 511.50K | 2.63M |
| Shares outstanding | 61.77M | 90.03M |
| Employees | 87 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Obsidian Therapeutics
OBX stock →Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
OBX vs SNDX FAQ
Which is bigger, Obsidian Therapeutics or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $741.29M for Obsidian Therapeutics (OBX).
Are Obsidian Therapeutics and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.